Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Reviving the guardian of the genome: Small molecule activators of p53.

Literature DB >> 28351719

Reviving the guardian of the genome: Small molecule activators of p53.

Daniel Nguyen¹, Wenjuan Liao¹, Shelya X Zeng¹, Hua Lu².

Abstract

The tumor suppressor p53 is one of the most important proteins for protection of genomic stability and cancer prevention. Cancers often inactivate it by either mutating its gene or disabling its function. Thus, activating p53 becomes an attractive approach for the development of molecule-based anti-cancer therapy. The past decade and half have witnessed tremendous progress in this area. This essay offers readers with a grand review on this progress with updated information about small molecule activators of p53 either still at bench work or in clinical trials.

Entities: Disease Gene

Keywords: Drug discovery; Inauhzin; MDM2; MDMX; Small molecules; p53

Mesh：

Substances：

Year: 2017 PMID： 28351719 PMCID： PMC5601031 DOI： 10.1016/j.pharmthera.2017.03.013

Source DB: PubMed Journal: Pharmacol Ther ISSN： 0163-7258 Impact factor: 12.310

280 in total

1. Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction.

Authors: Ana Z Gonzalez; John Eksterowicz; Michael D Bartberger; Hilary P Beck; Jude Canon; Ada Chen; David Chow; Jason Duquette; Brian M Fox; Jiasheng Fu; Xin Huang; Jonathan B Houze; Lixia Jin; Yihong Li; Zhihong Li; Yun Ling; Mei-Chu Lo; Alexander M Long; Lawrence R McGee; Joel McIntosh; Dustin L McMinn; Jonathan D Oliner; Tao Osgood; Yosup Rew; Anne Y Saiki; Paul Shaffer; Sarah Wortman; Peter Yakowec; Xuelei Yan; Qiuping Ye; Dongyin Yu; Xiaoning Zhao; Jing Zhou; Steven H Olson; Julio C Medina; Daqing Sun
Journal: J Med Chem Date: 2014-03-04 Impact factor: 7.446

Review 2. Transcriptional regulation by p53: one protein, many possibilities.

Authors: O Laptenko; C Prives
Journal: Cell Death Differ Date: 2006-06 Impact factor: 15.828

3. Scission of the p53-MDM2 Loop by Ribosomal Proteins.

Authors: Xiang Zhou; Jun-Ming Liao; Wen-Juan Liao; Hua Lu
Journal: Genes Cancer Date: 2012-03

4. Pilot screening programme for small molecule activators of p53.

Authors: Rachel G Berkson; Jonathan J Hollick; Nicholas J Westwood; Julie A Woods; David P Lane; Sonia Lain
Journal: Int J Cancer Date: 2005-07-10 Impact factor: 7.396

5. Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.

Authors: Min H Kang; C Patrick Reynolds; E Anders Kolb; Richard Gorlick; Hernan Carol; Richard Lock; Stephen T Keir; John M Maris; Jianwrong Wu; Dmitry Lyalin; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith
Journal: Pediatr Blood Cancer Date: 2016-05-30 Impact factor: 3.167

6. p53 domains: identification and characterization of two autonomous DNA-binding regions.

Authors: Y Wang; M Reed; P Wang; J E Stenger; G Mayr; M E Anderson; J F Schwedes; P Tegtmeyer
Journal: Genes Dev Date: 1993-12 Impact factor: 11.361

7. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding.

Authors: Wenge Wang; Rishu Takimoto; Farzan Rastinejad; Wafik S El-Deiry
Journal: Mol Cell Biol Date: 2003-03 Impact factor: 4.272

8. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.

Authors: S N Jones; A E Roe; L A Donehower; A Bradley
Journal: Nature Date: 1995-11-09 Impact factor: 49.962

9. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses.

Authors: Carlos P Rubbi; Jo Milner
Journal: EMBO J Date: 2003-11-17 Impact factor: 11.598

10. Determination of Maximum Tolerated Dose and Toxicity of Inauhzin in Mice.

Authors: Qi Zhang; Shelya X Zeng; Hua Lu
Journal: Toxicol Rep Date: 2015

21 in total

Review 1. Targeting MDM2 for novel molecular therapy: Beyond oncology.

Authors: Wei Wang; Jiang-Jiang Qin; Mehrdad Rajaei; Xin Li; Xiaoyi Yu; Courtney Hunt; Ruiwen Zhang
Journal: Med Res Rev Date: 2019-10-06 Impact factor: 12.944

Review 2. Targeted Therapy: Attacking Cancer with Molecular and Immunological Targeted Agents.

Authors: Gail M Wilkes
Journal: Asia Pac J Oncol Nurs Date: 2018 Apr-Jun

3. Differential protein-coding gene and long noncoding RNA expression in smoking-related lung squamous cell carcinoma.

Authors: Shicheng Li; Xiao Sun; Shuncheng Miao; Jia Liu; Wenjie Jiao
Journal: Thorac Cancer Date: 2017-09-26 Impact factor: 3.500

Review 4. Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine.

Authors: Jiang-Jiang Qin; Xin Li; Courtney Hunt; Wei Wang; Hui Wang; Ruiwen Zhang
Journal: Genes Dis Date: 2018-07-20

5. Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling.

Authors: Jing-Yue Yao; Shu Xu; Yue-Ning Sun; Ye Xu; Qing-Long Guo; Li-Bin Wei
Journal: Acta Pharmacol Sin Date: 2021-06-29 Impact factor: 6.150

Review 6. Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis.

Authors: Jahangir Abdi; Nasrin Rastgoo; Lihong Li; Wenming Chen; Hong Chang
Journal: J Hematol Oncol Date: 2017-10-26 Impact factor: 17.388

7. APTM, a Thiophene Heterocyclic Compound, Inhibits Human Colon Cancer HCT116 Cell Proliferation Through p53-Dependent Induction of Apoptosis.

Authors: Xiaolin Liao; Jiajun Huang; Wanjun Lin; Ze Long; Ying Xie; Wenzhe Ma
Journal: DNA Cell Biol Date: 2017-12-07 Impact factor: 3.311

8. Single-Nucleotide Polymorphism 309T>G in the MDM2 Promoter Determines Functional Outcome After Stroke.

Authors: Cristina Rodríguez; María E Ramos-Araque; Marta Domínguez-Martínez; Tomás Sobrino; Irene Sánchez-Morán; Jesús Agulla; María Delgado-Esteban; José C Gómez-Sánchez; Juan P Bolaños; José Castillo; Angeles Almeida
Journal: Stroke Date: 2018-10 Impact factor: 7.914

9. C₁₆-ceramide is a natural regulatory ligand of p53 in cellular stress response.

Authors: Baharan Fekry; Kristen A Jeffries; Amin Esmaeilniakooshkghazi; Zdzislaw M Szulc; Kevin J Knagge; David R Kirchner; David A Horita; Sergey A Krupenko; Natalia I Krupenko
Journal: Nat Commun Date: 2018-10-08 Impact factor: 14.919

10. CDK4 inhibition diminishes p53 activation by MDM2 antagonists.

Authors: Anusha Sriraman; Antje Dickmanns; Zeynab Najafova; Steven A Johnsen; Matthias Dobbelstein
Journal: Cell Death Dis Date: 2018-09-11 Impact factor: 8.469